Conseils, faits et astuces en santé et bien-être pour mener une vie équilibrée et confortable.
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. Today, we’re taking a look at some of
Following the success of Ozempic®, Wegovy®, and other GLP-1 receptor agonists, pharmaceutical companies are racing to develop the next wave of metabolic drugs. These new therapies build on the proven benefits of currently approved GLP-1s—lowering blood sugar, supporting weight loss, and reducing cardiovascular risk—while aiming for even greater results in weight management and metabolic health.
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. Today, we’re covering how someone might choose between GLP-1
Curious about the science behind today’s most talked-about diabetes and weight-management treatments? Our new, four-part blog series on GLP-1 Agonists will break down everything you need to know — from how these drugs work, to their real-world results, side effects, and what’s coming next in the pipeline. GLP-1 stands for glucagon-like peptide-1. It’s an incretin
A groundbreaking study from the University of Auckland has found that a single fecal microbiota transplant (FMT) can provide obese teenagers with years of health benefits. FMT involves transferring gut bacteria from healthy donors to patients—in this case, through capsules swallowed over two days. While the idea may sound unappealing, the results are remarkable. The
Eli Lilly is moving closer to bringing its experimental weight loss pill, orforglipron, to market after releasing positive results from its latest phase 3 clinical trial. The study, called Attain-2, tested the once-daily pill in people who are overweight or obese and also have Type 2 diabetes—a group often harder to treat. The trial found
The availability of COVID-19 vaccines for young children in the U.S. could shrink this fall as the Food and Drug Administration (FDA) considers ending the emergency use authorization (EUA) for Pfizer-BioNTech’s vaccine in kids ages 6 months to 4 years. Pfizer says it is in discussions with the FDA and has asked to keep the
A major new study has found that drinking just one can of diet soda a day may raise your risk of developing type 2 diabetes by 38%. Surprisingly, this is a greater risk than what’s seen with regular sugary sodas. The study, led by researchers at Monash University, followed more than 36,000 adults aged 40
A major new study from Denmark shows no link between aluminum in childhood vaccines and an increased risk of diseases like asthma or autism. Researchers examined health and vaccination records of over 1.2 million children from 1997 to 2018. They found no evidence that aluminum-containing vaccines cause harm. Aluminum salts are added to some vaccines
The FDA has approved a safer dosing schedule for Eli Lilly’s Alzheimer’s drug, Kisunla, which could make it more appealing to doctors and patients. The updated schedule reduces the risk of a serious side effect called ARIA-E—brain swelling caused by anti-amyloid drugs. Originally, Kisunla was given in higher doses early on. Now, the drug will
